For Q1 2026, AtriCure (ATRC) reported total revenue of US$141.2 million and basic EPS of about US$0.00, with net income excluding extra items at US$0.1 million. The trailing 12 months show revenue of US$552.2 million and a net loss of US$4.6 million with basic EPS of a US$0.10 loss. Over recent quarters, the company has seen revenue move from US$123.6 million in Q1 2025 to US$141.2 million in Q1 2026, while basic EPS has ranged from a loss of US$0.14 in Q1 2025 to about breakeven in the latest quarter. This sets up an earnings print where investors will focus closely on how sustainable the recent margin profile looks against a still loss-making 12 month backdrop.

See our full analysis for AtriCure.

Next up, the numbers are set against the widely followed AtriCure narratives to see which stories about growth, profitability and risk hold up under the latest earnings and which start to look stretched.

US$552.2m in sales still paired with TTM loss

• On a trailing 12 month basis, AtriCure generated US$552.2 million of revenue but reported a net loss of US$4.6 million and basic EPS of a US$0.10 loss.
• Consensus narrative points to operating leverage kicking in over time; however, the current mix of growing revenue and ongoing losses creates some tension with that view.
  • Analysts in the supplied data expect revenue to grow about 11% per year and earnings to grow 47.55% per year, with profitability expected within three years, while the latest trailing figures still show losses that have grown at about 17.4% per year over five years.
  • This combination supports the idea of a business investing heavily for growth, but it also means the path from today’s US$4.6 million loss to positive earnings remains a key execution test rather than something already visible in the trailing numbers.

Price at US$27.80 vs P/S of 2.5x

• With the share price at US$27.80, the trailing P/S is 2.5x, below the US Medical Equipment industry at 2.8x and the peer average at 3.6x, while the DCF fair value in the data is US$2.37.
• Bulls argue that lower P/S multiples and analyst targets support upside, but the DCF fair value figure pushes back on that optimism.
  • Analyst targets in the dataset center on US$47.00, which is well above the current US$27.80 price, yet the same dataset shows the share price sitting well above the DCF fair value of US$2.37.
  • That split gives you two very different valuation lenses, so if you lean toward the bullish case you will want to be comfortable that the analyst growth and margin assumptions justify paying a P/S premium to the DCF number.

Bulls see Q1 as another data point in a longer story about surgeons adopting new devices and revenue compounding, so if that angle interests you it is worth reading the full bullish case for how those trends could feed into margins and valuation over time. 🐂 AtriCure Bull Case

Five year loss growth vs bearish margin worries

• Over the past five years, trailing 12 month net losses have expanded at about 17.4% per year, and the latest four quarters together still show a US$4.6 million loss despite individual quarters like Q1 2026 landing roughly at breakeven.
• Bears focus on that loss trend and the risk that higher R&D and competitive pressure limit margin progress, and the trailing data gives some support to those concerns.
  • The quarterly path from a US$15.6 million loss in Q4 2024 to a roughly breakeven Q1 2026 suggests cost and margin management are actively moving, yet the full year view still nets out to a loss, which fits the cautious view that profitability is not yet established.
  • When you match that with a five year pattern of widening losses, it highlights why more cautious investors keep a close eye on how quickly expenses grow relative to revenue in upcoming periods.

Skeptical investors point to that multi year loss history and rising competition as reasons to be careful, so if you lean toward that side it helps to see the detailed cautious case laid out alongside the raw numbers. 🐻 AtriCure Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for AtriCure on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With all these moving parts, where does this leave your own view on AtriCure today? Take a closer look at what investors are optimistic about and weigh those positives against the risks by reviewing the 3 key rewards.

See What Else Is Out There

AtriCure pairs US$552.2m in trailing sales with a US$4.6m loss and mixed valuation signals, so profitability and value alignment still look uncertain.

If you want ideas where the financial profile lines up more cleanly with value, check out 51 high quality undervalued stocks today and compare alternatives side by side.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.